No Data
No Data
Express News | CANSINOBIO and Jenkem Technology are strategically cooperating to explore new solutions for mRNA vaccine tumor immunity.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiankai Technology: 2024 Annual Performance Report Announcement
2024 Annual Results Express Announcement
Jenkem Technology (688356.SH): A total of 0.2439% of shares have been repurchased. The company has completed this buyback.
Gelonghui, February 20丨Jenkem Technology (688356.SH) announced that as of the date of this announcement, the company has completed the current share repurchase, having repurchased a total of 0.147914 million shares through the centralized bidding trading system of the Shanghai Exchange, accounting for 0.2439% of the company's total share capital. The highest price for the repurchase was 75.05 yuan/share, the lowest price was 62.85 yuan/share, the average repurchase price was 70.99 yuan/share, and the total amount paid was 10,500,337.30 RMB (excluding transaction fees such as stamp duty and trading commission).